What are the targets of cabozantinib/cazantinib?

Cabozantinib, also known as XL184, is a multi-target small molecule tyrosine kinase inhibitor. It has been praised by the medical community and researchers as the "Taiwan Balm" among targeted drugs, mainly due to its inhibitory effect on multiple targets.

1.MET: MET is a tyrosine kinase receptor related to cell proliferation, migration and invasion. Cabozantinib inhibits the activity of MET, thereby slowing the growth and spread of tumors.

2.VEGFR1, VEGFR2, VEGFR3: These are vascular endothelial growth factor receptors that play a key role in tumor angiogenesis. By inhibiting these receptors, cabozantinib can reduce the blood supply to tumors, thereby inhibiting tumor growth.

3.ROS1: ROS1 is a receptor tyrosine kinase. In certain types of cancer, such as non-small cell lung cancer, the ROS1 gene will be rearranged, leading to abnormal cell proliferation. Cabozantinib inhibits this abnormal proliferation signal.

4.RET: RET is a common driver gene in neuroendocrine tumors. Cabozantinib can inhibit the activity of RET and has a significant therapeutic effect on tumors with RET gene mutations.

5.AXL, NTRK, KIT: These are tyrosine kinase receptors that are related to the occurrence and development of many cancers. By inhibiting these targets, cabozantinib can interfere with the signaling of tumor cells, thereby achieving anti-tumor effects.

Because cabozantinib targets so many targets, it has demonstrated significant clinical effects in a variety of solid tumors. Specifically, cabozantinib has a certain effect on liver cancer, soft tissue sarcoma, non-small cell lung cancer, etc. Especially in the treatment of medullary thyroid cancer, cabozantinib has proven to be very effective and can significantly extend the progression-free survival of patients.